Most patients with hereditary hemochromatosis are homozygous for C282Yin the HFEgene in populations of Celtic origin, but the genetic cause of this disease is unknown in Japan because of its rarity. A 48-year-old Japanese patient was recently diagnosed with idiopathic hemochromatosis. Analysis of the entire coding region of the patient's HFE by RT-PCR showed a heterozygous nucleotide substitution at nucleotide 527 from C to T, which resulted in A176Vamino acid substitution. Another mutation at nucleotide 942 from T to C was observed, but this was a nonsense mutation. C282Yand another mutation, H63D, were not found in the patient. The mutation may have a possible role on the cause of hemochromatosis in this Japanese case. (Internal Medicine 40: 479-483, 2001) 
Introduction
Hemochromatosis is characterized by inappropriately high iron absorption that leads to iron overload of manyorgans. Hereditary hemochromatosis is one of the most commoninherited diseases in the northern Europe population with a Celtic origin with a prevalence of approximately 1 : 300 and a carrier rate of 1: 12. In 1996 the gene hereditary hemochromatosis (HFE) was identified (1) . Two mutations, Cys282 to Tyr: C282Y (G to A at nucleotide 845) and His63 to Asp: H63D (C to G at nucleotide 187) have been described in this gene. Especially, many studies confirmed that the C282Ysubstitution was the main mutation in the development of hereditary hemochromatosis (2) (3) (4) . However, hereditary hemochromatosis can occur in adults who do not have C282Y or H63Dmutations. The C282Y substitution is absent in Asian people (5, 6) including Japanese (7) . Actually more than 10%of European and Asian patients with hemochromatosis do not have the mutations (8) (9) (10) . These findings suggest that Japanese hemochromatosis has the possibility of other mutations which have not yet been reported in the HFE gene. Recently, a Japanese man suffering from idiopathic hemochromatosis was found and treated by venesection at regular intervals, and the entire coding region of the patient's HFEgene was analyzed.
Case Report
Patient A 48-year-old Japanese manwas referred to our hospital because of liver dysfunction. There was no history of alcohol abuse, transfusions or excessive iron intake. There was no known family history of hereditary hemochromatosis or hereditary anemia. Physical examination showed mild hepatomegaly and gray-slaty pigmentation of the skin. There were no ascites or hepatic encephalopathy. Liver function tests (Table  1 ) revealed a mild elevation of aspartate aminotransferase 80 IU//, alanine aminotransferase 96 IU// and alkaline phosphatase 3.5 BLU. Total bilirubin was 0.8 mg/dl, albumin 3.8 g/dl and prothrombin time 69%. The patient had elevated serum iron 15 1 |Hg/dl (normal: 80-150), serum ferritin 6,487 ng/ml (normal: 29-181) and transferrin saturation 86% (normal: 20-45; transferrin saturation was calculated by dividing the serum iron concentration by the total serum iron-binding capacity). Results of serological tests for hepatitis B and C were negative. An oral glucose tolerance test showed a diabetic pattern. Computed tomographicscans of the abdomenshowedincreased hepatic CT density (Fig. 1A) . A liver biopsy was performed for diagnostic purposes and staging of his disease. The liver biopsy specimen was prepared with hematoxylin/eosin and berline blue staining. Histological examination of the liver biopsy specimen showed cirrhosis with massive hepatocellular siderosis: grade 3 (according to the classification of Scheuer) (1 1) as well as iron in bile duct cells and macrophages (Fig. 2) . The patient has been treated with phlebotomy of 300 ml of blood twice a month for approximately 2 years. Hepatic CT density (Fig. IB) and iron status improved after the treatment (ferritin: 6,487 ng/ml to 877 ng/ml; transferrin saturation: 86% to 60%).
Methods
Informed consent was obtained before taking the blood sample for HFEanalysis. The total RNAof the patient's peripheral white blood cells was extracted using an IsoQuick nucleic acid extraction kit (ORCAResearch, Bothell, WA, USA). Then mRNAwas purified from the total RNAusing Oligotex-dT30<super> (Takara, Otsu, Japan). Nested RT-PCR was performed with newly designed primers which covered the entire coding region of the HFE gene using a RNAPCR kit (AMV) Ver 2. 1 (Takara, Otsu, Japan) (Fig. 3) . The DNAsequences of the PCR primers were Fl After confirming the sizes and homogenity of the PCRproducts by agarose gel electrophoresis, direct sequencing of the entire coding region of the patient's HFEgene was performed using PCRprimers and a Dyeterminator cycle sequencing core kit (Perkin-Elmer, Branchburg, NJ, USA) and ABI 373 DNA sequencer. Sequences were determined for both sense and antisense strands. The data were analyzed using DNASIS-MAC v3.6. Blood samples from four volunteers were also used as normal controls after informed consent.
Results Twopoint mutations were observed in comparison with the sequence of the reported HFE gene (GenBank accession number U60319) (Fig. 4) . The first point mutation was C to T transition at nucleotide 527 resulting in the substitution of valine for alanine at amino acid 176. [Weused the numberingsystem which began at initial methionine.] This Alal76Val (A176V) mutation was a heterozygote.
The second mutation, a homozygous mutation, was T to C transition at nucleotide 942, but this mutation did not result in amino acid change. Normal control subjects did not have any nucleotide change in the HFEgene. The C282Yand H63D mutations were not observed in the patient's HFE.
Discussion
Most patients with hereditary hemochromatosis are homozygous mutation (C282Y/C282Y) or compound heterozygous mutation (C282Y/H63D) of the HFE gene in populations of northern European origin. However, more than 10%of European patients with hemochromatosis and most Asian patients with this disease do not have the C282Ymutation. The possibility of a new mutation in the HFEgene has been raised to explain the disease without C282Ymutation. Here, we report heterozygous A176Vmutation in a Japanese patient with idiopathic hemochromatosis. The first discussion point is that the mutation mayrepresent only a polymorphic variant. Several studies for systemic sequencing of the HFEgene showed several mutations of the HFE gene in addition to C282Y and H63D (12, 13) . These are predominantly localized in intron sequences except for Ser65Cys (S65C) in exon 2. Although S65Cis initially thought to represent only a polymorphic variant, Mura et al (14) suggested that S65C substitution is associated with the mild form of hemochromatosis. [S65C mutation was not found in our patient.] Therefore, we suspect that A 176Vsubstitution could be a contributing factor to iron overload in hemochromatosispatients like S65C.
The second point is that the A176V is heterozygous in our patient. As for the C282Ymutation, serum markers of iron status (ferritin and transferrin saturation) were shown to be higher in people heterozygous for C282Ythan in people homozygous for wild type (15) . However, the levels of serum ferritin and transferrin saturation werenot as high as those in people homozygous for C282Y. The mutation found in our patient was heterozygous for the HFEgene, but the levels of serum markers of iron status were as high as those of the patients whose mutation is homozygous for C282Y. It is unclear whether the A176Vheterozygous mutation contributed to iron overload. Although a heterozygote of A 1 76Vsubstitution maypossibly increase the risk of developing hemochromatosis, a genetic mutation other than the HFEgene must be studied in order to clarify the meaning of A 1 76V mutation. The present case may present only a private mutation. However, it is worth reporting because of the rarity of idiopathic hemochromatosis in Japan. This is the first report of a Japanese patient with idiopathic hemochromatosiswhose entire coding region of the HFEgene was analyzed.
